| Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer K Moore, N Colombo, G Scambia, BG Kim, A Oaknin, M Friedlander, ... New England Journal of Medicine 379 (26), 2495-2505, 2018 | 2759 | 2018 |
| A phase 3 trial of bevacizumab in ovarian cancer TJ Perren, AM Swart, J Pfisterer, JA Ledermann, E Pujade-Lauraine, ... New England Journal of Medicine 365 (26), 2484-2496, 2011 | 2694 | 2011 |
| Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer MR Mirza, BJ Monk, J Herrstedt, AM Oza, S Mahner, A Redondo, ... New England Journal of Medicine 375 (22), 2154-2164, 2016 | 2659 | 2016 |
| Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial C Zimmermann, N Swami, M Krzyzanowska, B Hannon, N Leighl, A Oza, ... The Lancet 383 (9930), 1721-1730, 2014 | 1946 | 2014 |
| Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised … E Pujade-Lauraine, JA Ledermann, F Selle, V Gebski, RT Penson, ... The lancet oncology 18 (9), 1274-1284, 2017 | 1823 | 2017 |
| Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial RL Coleman, AM Oza, D Lorusso, C Aghajanian, A Oaknin, A Dean, ... The Lancet 390 (10106), 1949-1961, 2017 | 1774 | 2017 |
| Epithelial ovarian cancer S Lheureux, C Gourley, I Vergote, AM Oza The Lancet 393 (10177), 1240-1253, 2019 | 1648 | 2019 |
| Rethinking ovarian cancer: recommendations for improving outcomes S Vaughan, JI Coward, RC Bast Jr, A Berchuck, JS Berek, JD Brenton, ... Nature Reviews Cancer 11 (10), 719-725, 2011 | 1568 | 2011 |
| Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non … KA Gelmon, M Tischkowitz, H Mackay, K Swenerton, A Robidoux, ... The lancet oncology 12 (9), 852-861, 2011 | 1377 | 2011 |
| Epithelial ovarian cancer: evolution of management in the era of precision medicine S Lheureux, M Braunstein, AM Oza CA: a cancer journal for clinicians 69 (4), 280-304, 2019 | 1374 | 2019 |
| Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial EM Swisher, KK Lin, AM Oza, CL Scott, H Giordano, J Sun, GE Konecny, ... The lancet oncology 18 (1), 75-87, 2017 | 1234 | 2017 |
| Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial AM Oza, AD Cook, J Pfisterer, A Embleton, JA Ledermann, ... The Lancet Oncology 16 (8), 928-936, 2015 | 988 | 2015 |
| Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil … ML Rothenberg, AM Oza, RH Bigelow, JD Berlin, JL Marshall, ... Journal of Clinical Oncology 21 (11), 2059-2069, 2003 | 850 | 2003 |
| The statins as anticancer agents KKW Chan, AM Oza, LL Siu Clinical cancer research 9 (1), 10-19, 2003 | 766 | 2003 |
| Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret … AA Garcia, H Hirte, G Fleming, D Yang, DD Tsao-Wei, L Roman, ... Journal of Clinical Oncology 26 (1), 76-82, 2008 | 688 | 2008 |
| Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial AM Oza, D Cibula, AO Benzaquen, C Poole, RHJ Mathijssen, GS Sonke, ... The lancet oncology 16 (1), 87-97, 2015 | 650 | 2015 |
| 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG … A Du Bois, M Quinn, T Thigpen, J Vermorken, E Avall-Lundqvist, ... Annals of oncology 16, viii7-viii12, 2005 | 559 | 2005 |
| Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial KN Moore, AA Secord, MA Geller, DS Miller, N Cloven, GF Fleming, ... The Lancet Oncology 20 (5), 636-648, 2019 | 516 | 2019 |
| Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study W Sieh, M Köbel, TA Longacre, DD Bowtell, A DeFazio, MT Goodman, ... The lancet oncology 14 (9), 853-862, 2013 | 488 | 2013 |
| Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian … O Kondrashova, M Nguyen, K Shield-Artin, AV Tinker, NNH Teng, ... Cancer discovery 7 (9), 984-998, 2017 | 406 | 2017 |
